Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by National Cancer Institute (NCI)
Sponsor
National Cancer Institute (NCI)
Information Provided by (Responsible Party)
National Cancer Institute (NCI)
Clinicaltrials.gov Identifier
NCT06422806
Other Study ID Numbers:
NCI-2023-06412
First Submitted
May 17, 2024
First Posted
May 20, 2024
Last Update Posted
April 30, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

PRIMARY OBJECTIVES:

I. To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival (PFS) in UPS and related poorly differentiated sarcomas relative to doxorubicin alone.

II. To assess whether the combination of doxorubicin and pembrolizumab will improve PFS in DDLPS relative to doxorubicin alone.

KEY SECONDARY OBJECTIVE:

I. To assess whether the combination of doxorubicin and pembrolizumab versus (vs) the re-introduction of pembrolizumab in the doxorubicin alone arm at disease progression (i.e., upfront pembrolizumab vs second line pembrolizumab) improves overall survival (OS) in DDLPS and the UPS family of diseases.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability in each treatment arm. II. To quantify overall response rate (ORR) and durability of response (DOR) in each treatment.

EXPLORATORY OBJECTIVES:

I. To evaluate the agreement between the central review and local Response Evaluation Criteria in Solid Tumors (RECIST) assessments for patients identified for central imaging review.

II. To compare PFS, OS, ORR and DOR of doxorubicin with or without pembrolizumab for all patients, combining the UPS and DDLPS patients together.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive doxorubicin intravenously (IV) over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. At time of disease progression, patients may begin receiving pembrolizumab alone IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of additional progression or unacceptable toxicity.

Patients in both arms also undergo echocardiography (ECHO) or multigated acquisition (MUGA) scan, standard imaging scans and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months in years 2-10.

Condition or DiseaseIntervention/Treatment
Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Unresectable Dedifferentiated LiposarcomaUnresectable Undifferentiated Pleomorphic Sarcoma
Procedure: Biospecimen CollectionProcedure: Biospecimen Collection

Study Design

Study TypeInterventional
Actual Enrollment365 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Study Start DateSeptember 10, 2024
Actual Primary Completion Date1mo 3w from now
Actual Study Completion Date1mo 3w from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Arm A (doxorubicin and pembrolizumab
Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan, standard imaging scans and blood sample collection throughout the study.
Procedure: Biospecimen Collection
Undergo blood sample collection
Arm B (doxorubicin)
Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. At time of disease progression, patients may begin receiving pembrolizumab alone IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of additional progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan, standard imaging scans and blood sample collection throughout the study.
Procedure: Biospecimen Collection
Undergo blood sample collection

Outcome Measures

Primary Outcome Measures
  1. Progression free survival (PFS)
    Will be compared between the treatment arms (doxorubicin + pembrolizumab versus \[vs\] doxorubicin alone). The comparison of PFS between treatment arms will be done using a stratified (on Eastern Cooperative Oncology group performance status \[0 vs 1\]) log-rank test with a 2.5% type I error (1-sided). Will be analyzed separately for the undifferentiated pleomorphic sarcoma and related malignancies and for the dedifferentiated liposarcoma.
Secondary Outcome Measures
  1. Overall survival
    Will be compared between doxorubicin + pembrolizumab vs doxorubicin alone to test the strategy of upfront pembrolizumab vs second line pembrolizumab.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Patient must be \>= 18 years of age
Patient must have a confirmed histopathologic diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to:
Pleomorphic sarcoma with inflammation or with limited areas of differentiation
Pleomorphic sarcoma with giant cells
Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
Myxofibrosarcoma
Poorly differentiated sarcoma not otherwise specified (NOS)
Undifferentiated spindle cell sarcoma
Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation
Patient must have metastatic or unresectable sarcoma
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:
Has achieved menarche at some point
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of child bearing potential and for 3 months after the last dose of doxorubicin for male patients with partners of child bearing potential. Males with pregnant partners should use condoms during doxorubicin treatment and for at least 10 days after the last dose of doxorubicin. Contraception measures must also continue for 4 months after the last dose of pembrolizumab for patients of child bearing potential
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Patient must have a left ventricular ejection fraction (LVEF) \> 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization
Absolute neutrophil count (ANC) ≥ 1,500 cells/uL (must be obtained ≤ 7 days prior to protocol randomization)
Platelets ≥ 75,000 cells/uL (must be obtained ≤ 7 days prior to protocol randomization)
Total bilirubin \< 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional upper limit of normal (ULN) (must be obtained ≤ 7 days prior to protocol randomization)
Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization)
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Patient must not have a history of or active interstitial lung disease
Patient must have measurable disease. Baseline imaging must include a chest computed tomography (CT). Imaging should be inclusive of all measurable and non-measurable disease and must be obtained within 28 days prior to randomization. Imaging must be available for uploading to Transfer of Images and Data (TRIAD)
NOTE: CT with (w/) contrast preferred, chest CT without contrast is acceptable, CT portion of positron emission tomography (PET) may be acceptable. Magnetic resonance imaging (MRI) is acceptable for measuring other sites of disease
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Patient must not have had prior treatment with an anthracycline
Patient must not have a diagnosis of clinically significant immunodeficiency or an autoimmune disorder requiring the patient to use systemic steroid chronically, or systemic steroids within 7 days prior to randomization
Patient must not have a known history of active TB (Bacillus Tuberculosis)
Patient must not have a known hypersensitivity to doxorubicin or pembrolizumab or any of their excipients
Patients who have received prior chemotherapy, targeted small molecule therapy or radiation therapy must have recovered from the prior therapy at the time of randomization
Patient must have recovered adequately from any prior major surgery prior to randomization
Patient must not have had prior pericardial or mediastinal radiation
Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent
Patient must not have an autoimmune or other disease that requires the use of daily corticosteroids of \> 10 mg of prednisone (or equivalent). Patients who are on an active steroid taper at the time of randomization must finish prior to beginning study treatment. Patients who require inhaled or topical steroids are eligible
Exclusion Criteria
Inclusion Criteria:
Patient must be \>= 18 years of age
Patient must have a confirmed histopathologic diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to:
Pleomorphic sarcoma with inflammation or with limited areas of differentiation
Pleomorphic sarcoma with giant cells
Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
Myxofibrosarcoma
Poorly differentiated sarcoma not otherwise specified (NOS)
Undifferentiated spindle cell sarcoma
Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation
Patient must have metastatic or unresectable sarcoma
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:
Has achieved menarche at some point
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of child bearing potential and for 3 months after the last dose of doxorubicin for male patients with partners of child bearing potential. Males with pregnant partners should use condoms during doxorubicin treatment and for at least 10 days after the last dose of doxorubicin. Contraception measures must also continue for 4 months after the last dose of pembrolizumab for patients of child bearing potential
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Patient must have a left ventricular ejection fraction (LVEF) \> 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization
Absolute neutrophil count (ANC) ≥ 1,500 cells/uL (must be obtained ≤ 7 days prior to protocol randomization)
Platelets ≥ 75,000 cells/uL (must be obtained ≤ 7 days prior to protocol randomization)
Total bilirubin \< 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional upper limit of normal (ULN) (must be obtained ≤ 7 days prior to protocol randomization)
Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization)
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Patient must not have a history of or active interstitial lung disease
Patient must have measurable disease. Baseline imaging must include a chest computed tomography (CT). Imaging should be inclusive of all measurable and non-measurable disease and must be obtained within 28 days prior to randomization. Imaging must be available for uploading to Transfer of Images and Data (TRIAD)
NOTE: CT with (w/) contrast preferred, chest CT without contrast is acceptable, CT portion of positron emission tomography (PET) may be acceptable. Magnetic resonance imaging (MRI) is acceptable for measuring other sites of disease
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Patient must not have had prior treatment with an anthracycline
Patient must not have a diagnosis of clinically significant immunodeficiency or an autoimmune disorder requiring the patient to use systemic steroid chronically, or systemic steroids within 7 days prior to randomization
Patient must not have a known history of active TB (Bacillus Tuberculosis)
Patient must not have a known hypersensitivity to doxorubicin or pembrolizumab or any of their excipients
Patients who have received prior chemotherapy, targeted small molecule therapy or radiation therapy must have recovered from the prior therapy at the time of randomization
Patient must have recovered adequately from any prior major surgery prior to randomization
Patient must not have had prior pericardial or mediastinal radiation
Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent
Patient must not have an autoimmune or other disease that requires the use of daily corticosteroids of \> 10 mg of prednisone (or equivalent). Patients who are on an active steroid taper at the time of randomization must finish prior to beginning study treatment. Patients who require inhaled or topical steroids are eligible

Contacts and Locations

Sponsors and CollaboratorsNational Cancer Institute (NCI)
Locations
Mayo Clinic Hospital in Arizona | Phoenix Arizona, United States, 85054Banner University Medical Center - Tucson | Tucson Arizona, United States, 85719University of Arizona Cancer Center-North Campus | Tucson Arizona, United States, 85719Kaiser Permanente Dublin | Dublin California, United States, 94568Kaiser Permanente-Fremont | Fremont California, United States, 94538Kaiser Permanente Fresno Orchard Plaza | Fresno California, United States, 93720Kaiser Permanente-Fresno | Fresno California, United States, 93720UC San Diego Moores Cancer Center | La Jolla California, United States, 92093Keck Medicine of USC Koreatown | Los Angeles California, United States, 90020Los Angeles General Medical Center | Los Angeles California, United States, 90033USC / Norris Comprehensive Cancer Center | Los Angeles California, United States, 90033Cedars Sinai Medical Center | Los Angeles California, United States, 90048Kaiser Permanente- Modesto MOB II | Modesto California, United States, 95356Kaiser Permanente-Modesto | Modesto California, United States, 95356USC Norris Oncology/Hematology-Newport Beach | Newport Beach California, United States, 92663Kaiser Permanente-Oakland | Oakland California, United States, 94611Stanford Cancer Institute Palo Alto | Palo Alto California, United States, 94304VA Palo Alto Health Care System | Palo Alto California, United States, 94304Huntington Memorial Hospital | Pasadena California, United States, 91105Kaiser Permanente-Roseville | Roseville California, United States, 95661Kaiser Permanente Downtown Commons | Sacramento California, United States, 95814Kaiser Permanente-South Sacramento | Sacramento California, United States, 95823Kaiser Permanente-San Francisco | San Francisco California, United States, 94115UCSF Medical Center-Mission Bay | San Francisco California, United States, 94158Kaiser Permanente-Santa Teresa-San Jose | San Jose California, United States, 95119Kaiser Permanente San Leandro | San Leandro California, United States, 94577Kaiser San Rafael-Gallinas | San Rafael California, United States, 94903Kaiser Permanente Medical Center - Santa Clara | Santa Clara California, United States, 95051Kaiser Permanente-Santa Rosa | Santa Rosa California, United States, 95403Kaiser Permanente-South San Francisco | South San Francisco California, United States, 94080Kaiser Permanente-Vallejo | Vallejo California, United States, 94589Kaiser Permanente-Walnut Creek | Walnut Creek California, United States, 94596UCHealth University of Colorado Hospital | Aurora Colorado, United States, 80045Poudre Valley Hospital | Fort Collins Colorado, United States, 80524Cancer Care and Hematology-Fort Collins | Fort Collins Colorado, United States, 80528UCHealth Greeley Hospital | Greeley Colorado, United States, 80631Medical Center of the Rockies | Loveland Colorado, United States, 80538Smilow Cancer Hospital-Derby Care Center | Derby Connecticut, United States, 06418Smilow Cancer Hospital Care Center-Fairfield | Fairfield Connecticut, United States, 06824Smilow Cancer Hospital Care Center at Greenwich | Greenwich Connecticut, United States, 06830Smilow Cancer Hospital Care Center - Guilford | Guilford Connecticut, United States, 06437Yale University | New Haven Connecticut, United States, 06520Smilow Cancer Hospital Care Center at Long Ridge | Stamford Connecticut, United States, 06902Smilow Cancer Hospital-Torrington Care Center | Torrington Connecticut, United States, 06790Smilow Cancer Hospital Care Center-Trumbull | Trumbull Connecticut, United States, 06611Smilow Cancer Hospital-Waterbury Care Center | Waterbury Connecticut, United States, 06708Smilow Cancer Hospital Care Center - Waterford | Waterford Connecticut, United States, 06385Beebe South Coastal Health Campus | Millville Delaware, United States, 19967Helen F Graham Cancer Center | Newark Delaware, United States, 19713Medical Oncology Hematology Consultants PA | Newark Delaware, United States, 19713Beebe Health Campus | Rehoboth Beach Delaware, United States, 19971UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables Florida, United States, 33146UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs Florida, United States, 33065UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach Florida, United States, 33442UF Health Cancer Institute - Gainesville | Gainesville Florida, United States, 32610UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood Florida, United States, 33021Mayo Clinic in Florida | Jacksonville Florida, United States, 32224-9980University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami Florida, United States, 33136UM Sylvester Comprehensive Cancer Center at Kendall | Miami Florida, United States, 33176University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami Florida, United States, 33181UM Sylvester Comprehensive Cancer Center at Plantation | Plantation Florida, United States, 33324Moffitt Cancer Center - McKinley Campus | Tampa Florida, United States, 33612Moffitt Cancer Center | Tampa Florida, United States, 33612Emory University Hospital Midtown | Atlanta Georgia, United States, 30308Kaiser Permanente Moanalua Medical Center | Honolulu Hawaii, United States, 96819Saint Alphonsus Cancer Care Center-Boise | Boise Idaho, United States, 83706Saint Alphonsus Cancer Care Center-Caldwell | Caldwell Idaho, United States, 83605Kootenai Health - Coeur d'Alene | Coeur d'Alene Idaho, United States, 83814Saint Alphonsus Cancer Care Center-Nampa | Nampa Idaho, United States, 83687Kootenai Clinic Cancer Services - Post Falls | Post Falls Idaho, United States, 83854Kootenai Clinic Cancer Services - Sandpoint | Sandpoint Idaho, United States, 83864Advocate Outpatient Center - Aurora | Aurora Illinois, United States, 60506Advocate Good Shepherd Hospital | Barrington Illinois, United States, 60010Illinois CancerCare-Bloomington | Bloomington Illinois, United States, 61704Illinois CancerCare-Canton | Canton Illinois, United States, 61520Illinois CancerCare-Carthage | Carthage Illinois, United States, 62321Centralia Oncology Clinic | Centralia Illinois, United States, 62801Northwestern University | Chicago Illinois, United States, 60611University of Illinois | Chicago Illinois, United States, 60612University of Chicago Comprehensive Cancer Center | Chicago Illinois, United States, 60637Advocate Illinois Masonic Medical Center | Chicago Illinois, United States, 60657AMG Crystal Lake - Oncology | Crystal Lake Illinois, United States, 60014Carle at The Riverfront | Danville Illinois, United States, 61832Cancer Care Specialists of Illinois - Decatur | Decatur Illinois, United States, 62526Decatur Memorial Hospital | Decatur Illinois, United States, 62526Northwestern Medicine Cancer Center Kishwaukee | DeKalb Illinois, United States, 60115Illinois CancerCare-Dixon | Dixon Illinois, United States, 61021Advocate Good Samaritan Hospital | Downers Grove Illinois, United States, 60515Carle Physician Group-Effingham | Effingham Illinois, United States, 62401Crossroads Cancer Center | Effingham Illinois, United States, 62401Advocate Sherman Hospital | Elgin Illinois, United States, 60123Elmhurst Memorial Hospital | Elmhurst Illinois, United States, 60126Illinois CancerCare-Eureka | Eureka Illinois, United States, 61530Illinois CancerCare-Galesburg | Galesburg Illinois, United States, 61401Northwestern Medicine Cancer Center Delnor | Geneva Illinois, United States, 60134Northwestern Medicine Glenview Outpatient Center | Glenview Illinois, United States, 60026Northwestern Medicine Grayslake Outpatient Center | Grayslake Illinois, United States, 60030Ingalls Memorial Hospital | Harvey Illinois, United States, 60426Advocate South Suburban Hospital | Hazel Crest Illinois, United States, 60429Illinois CancerCare-Kewanee Clinic | Kewanee Illinois, United States, 61443Northwestern Medicine Lake Forest Hospital | Lake Forest Illinois, United States, 60045AMG Libertyville - Oncology | Libertyville Illinois, United States, 60048Condell Memorial Hospital | Libertyville Illinois, United States, 60048Illinois CancerCare-Macomb | Macomb Illinois, United States, 61455Carle Physician Group-Mattoon/Charleston | Mattoon Illinois, United States, 61938Edward Hospital/Cancer Center | Naperville Illinois, United States, 60540UC Comprehensive Cancer Center at Silver Cross | New Lenox Illinois, United States, 60451Cancer Care Center of O'Fallon | O'Fallon Illinois, United States, 62269Advocate Christ Medical Center | Oak Lawn Illinois, United States, 60453-2699Northwestern Medicine Orland Park | Orland Park Illinois, United States, 60462University of Chicago Medicine-Orland Park | Orland Park Illinois, United States, 60462Illinois CancerCare-Ottawa Clinic | Ottawa Illinois, United States, 61350Advocate Lutheran General Hospital | Park Ridge Illinois, United States, 60068Illinois CancerCare-Pekin | Pekin Illinois, United States, 61554Illinois CancerCare-Peoria | Peoria Illinois, United States, 61615Illinois CancerCare-Peru | Peru Illinois, United States, 61354Edward Hospital/Cancer Center?Plainfield | Plainfield Illinois, United States, 60585Illinois CancerCare-Princeton | Princeton Illinois, United States, 61356Southern Illinois University School of Medicine | Springfield Illinois, United States, 62702Springfield Clinic | Springfield Illinois, United States, 62702Springfield Memorial Hospital | Springfield Illinois, United States, 62781Carle Cancer Center | Urbana Illinois, United States, 61801Northwestern Medicine Cancer Center Warrenville | Warrenville Illinois, United States, 60555Illinois CancerCare - Washington | Washington Illinois, United States, 61571UChicago Medicine Northwest Indiana | Crown Point Indiana, United States, 46307Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis Indiana, United States, 46202Sidney and Lois Eskenazi Hospital | Indianapolis Indiana, United States, 46202UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny Iowa, United States, 50023Saint Anthony Regional Hospital | Carroll Iowa, United States, 51401UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive Iowa, United States, 50325UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines Iowa, United States, 50309Broadlawns Medical Center | Des Moines Iowa, United States, 50314UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines Iowa, United States, 50314UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge Iowa, United States, 50501University of Iowa/Holden Comprehensive Cancer Center | Iowa City Iowa, United States, 52242UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee Iowa, United States, 50263The James Graham Brown Cancer Center at University of Louisville | Louisville Kentucky, United States, 40202UofL Health Medical Center Northeast | Louisville Kentucky, United States, 40245Louisiana Hematology Oncology Associates LLC | Baton Rouge Louisiana, United States, 70809Dana-Farber Cancer Institute | Boston Massachusetts, United States, 02215University of Michigan Rogel Cancer Center | Ann Arbor Michigan, United States, 48109Henry Ford Cancer Institute-Downriver | Brownstown Michigan, United States, 48183Henry Ford Macomb Hospital-Clinton Township | Clinton Township Michigan, United States, 48038Henry Ford Medical Center-Fairlane | Dearborn Michigan, United States, 48126Henry Ford Hospital | Detroit Michigan, United States, 48202Allegiance Health | Jackson Michigan, United States, 49201Henry Ford Medical Center-Columbus | Novi Michigan, United States, 48377Henry Ford West Bloomfield Hospital | West Bloomfield Michigan, United States, 48322Henry Ford Wyandotte Hospital | Wyandotte Michigan, United States, 48192Sanford Joe Lueken Cancer Center | Bemidji Minnesota, United States, 56601Essentia Health - Deer River Clinic | Deer River Minnesota, United States, 56636Essentia Health Cancer Center | Duluth Minnesota, United States, 55805Essentia Health Hibbing Clinic | Hibbing Minnesota, United States, 55746Mayo Clinic in Rochester | Rochester Minnesota, United States, 55905Essentia Health Sandstone | Sandstone Minnesota, United States, 55072Essentia Health Virginia Clinic | Virginia Minnesota, United States, 55792Siteman Cancer Center at West County Hospital | Creve Coeur Missouri, United States, 63141Washington University School of Medicine | St Louis Missouri, United States, 63110Siteman Cancer Center-South County | St Louis Missouri, United States, 63129Community Hospital of Anaconda | Anaconda Montana, United States, 59711Billings Clinic Cancer Center | Billings Montana, United States, 59101Bozeman Health Deaconess Hospital | Bozeman Montana, United States, 59715Benefis Sletten Cancer Institute | Great Falls Montana, United States, 59405Logan Health Medical Center | Kalispell Montana, United States, 59901Community Medical Center | Missoula Montana, United States, 59804Nebraska Medicine-Bellevue | Bellevue Nebraska, United States, 68123Nebraska Medicine-Village Pointe | Omaha Nebraska, United States, 68118University of Nebraska Medical Center | Omaha Nebraska, United States, 68198Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon New Hampshire, United States, 03756Memorial Sloan Kettering Basking Ridge | Basking Ridge New Jersey, United States, 07920Memorial Sloan Kettering Bergen | Montvale New Jersey, United States, 07645University of New Mexico Cancer Center | Albuquerque New Mexico, United States, 87106Roswell Park Cancer Institute | Buffalo New York, United States, 14263Northwell Health/Center for Advanced Medicine | Lake Success New York, United States, 11042Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York New York, United States, 10016Memorial Sloan Kettering Cancer Center | New York New York, United States, 10065University of Rochester | Rochester New York, United States, 14642Montefiore Medical Center-Einstein Campus | The Bronx New York, United States, 10461Montefiore Medical Center - Moses Campus | The Bronx New York, United States, 10467Memorial Sloan Kettering Nassau | Uniondale New York, United States, 11553Duke University Medical Center | Durham North Carolina, United States, 27710Sanford Bismarck Medical Center | Bismarck North Dakota, United States, 58501Sanford Broadway Medical Center | Fargo North Dakota, United States, 58122Sanford Roger Maris Cancer Center | Fargo North Dakota, United States, 58122UH Seidman Cancer Center at UH Avon Health Center | Avon Ohio, United States, 44011UHHS-Chagrin Highlands Medical Center | Beachwood Ohio, United States, 44122Miami Valley Hospital South | Centerville Ohio, United States, 45459Case Western Reserve University | Cleveland Ohio, United States, 44106Cleveland Clinic Foundation | Cleveland Ohio, United States, 44195Ohio State University Comprehensive Cancer Center | Columbus Ohio, United States, 43210Miami Valley Hospital | Dayton Ohio, United States, 45409Premier Blood and Cancer Center | Dayton Ohio, United States, 45409Miami Valley Hospital North | Dayton Ohio, United States, 45415Atrium Medical Center-Middletown Regional Hospital | Franklin Ohio, United States, 45005-1066Miami Valley Cancer Care and Infusion | Greenville Ohio, United States, 45331Upper Valley Medical Center | Troy Ohio, United States, 45373University of Oklahoma Health Sciences Center | Oklahoma City Oklahoma, United States, 73104Saint Alphonsus Cancer Care Center-Ontario | Ontario Oregon, United States, 97914Oregon Health and Science University | Portland Oregon, United States, 97239Pennsylvania Hospital | Philadelphia Pennsylvania, United States, 19107Thomas Jefferson University Hospital | Philadelphia Pennsylvania, United States, 19107Fox Chase Cancer Center | Philadelphia Pennsylvania, United States, 19111Allegheny General Hospital | Pittsburgh Pennsylvania, United States, 15212University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh Pennsylvania, United States, 15232Medical University of South Carolina | Charleston South Carolina, United States, 29425Sanford Cancer Center Oncology Clinic | Sioux Falls South Dakota, United States, 57104Sanford USD Medical Center - Sioux Falls | Sioux Falls South Dakota, United States, 57117-5134Vanderbilt University/Ingram Cancer Center | Nashville Tennessee, United States, 37232University of Virginia Cancer Center | Charlottesville Virginia, United States, 22908VCU Massey Comprehensive Cancer Center | Richmond Virginia, United States, 23298ThedaCare Regional Cancer Center | Appleton Wisconsin, United States, 54911Duluth Clinic Ashland | Ashland Wisconsin, United States, 54806Aurora Cancer Care-Southern Lakes VLCC | Burlington Wisconsin, United States, 53105Aurora Saint Luke's South Shore | Cudahy Wisconsin, United States, 53110Marshfield Medical Center-EC Cancer Center | Eau Claire Wisconsin, United States, 54701Aurora Health Care Germantown Health Center | Germantown Wisconsin, United States, 53022Aurora Cancer Care-Grafton | Grafton Wisconsin, United States, 53024Aurora BayCare Medical Center | Green Bay Wisconsin, United States, 54311Aurora Cancer Care-Kenosha South | Kenosha Wisconsin, United States, 53142Aurora Bay Area Medical Group-Marinette | Marinette Wisconsin, United States, 54143Marshfield Medical Center-Marshfield | Marshfield Wisconsin, United States, 54449Aurora Cancer Care-Milwaukee | Milwaukee Wisconsin, United States, 53209Aurora Saint Luke's Medical Center | Milwaukee Wisconsin, United States, 53215Medical College of Wisconsin | Milwaukee Wisconsin, United States, 53226Aurora Sinai Medical Center | Milwaukee Wisconsin, United States, 53233ProHealth D N Greenwald Center | Mukwonago Wisconsin, United States, 53149ProHealth Oconomowoc Memorial Hospital | Oconomowoc Wisconsin, United States, 53066Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh Wisconsin, United States, 54904Aurora Cancer Care-Racine | Racine Wisconsin, United States, 53406Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan Wisconsin, United States, 53081Marshfield Medical Center-River Region at Stevens Point | Stevens Point Wisconsin, United States, 54482Aurora Medical Center in Summit | Summit Wisconsin, United States, 53066Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers Wisconsin, United States, 54241ProHealth Waukesha Memorial Hospital | Waukesha Wisconsin, United States, 53188UW Cancer Center at ProHealth Care | Waukesha Wisconsin, United States, 53188Aurora Cancer Care-Milwaukee West | Wauwatosa Wisconsin, United States, 53226Aurora West Allis Medical Center | West Allis Wisconsin, United States, 53227Marshfield Medical Center - Weston | Weston Wisconsin, United States, 54476Arthur J E Child Comprehensive Cancer Centre | Calgary Alberta, Canada, T2N 5G2Cross Cancer Institute | Edmonton Alberta, Canada, T6G 1Z2CancerCare Manitoba | Winnipeg Manitoba, Canada, R3E 0V9Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton Ontario, Canada, L8V 5C2Ottawa Hospital and Cancer Center-General Campus | Ottawa Ontario, Canada, K1H 8L6University Health Network-Princess Margaret Hospital | Toronto Ontario, Canada, M5G 2M9CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) | Québec Quebec, Canada, G1R 2J6Pan American Center for Oncology Trials LLC - Dorado | Dorado , Puerto Rico, 00646Pan American Center for Oncology Trials LLC | San Juan , Puerto Rico, 00902Pan American Center for Oncology Trials LLC - Ciudadela | San Juan , Puerto Rico, 00909
Investigators
Principal Investigator: Seth M Pollack, ECOG-ACRIN Cancer Research Group